Hovione Technology, a specialist in development of inhalation device technology, has announced it has secured global rights to develop and commercialise a new multi-use blister-based dry powder inhaler patented by inventor Dr. Klaus-Dieter Beller.

The two parties will continue to collaborate on the inhaler, which will be marketed as the Papillon DPI.

The Papillon DPI is a single-part, blister-based, reusable inhaler of extreme simplicity, suitable for both chronic and acute treatments. It can accommodate a single or double blister configuration, enabling ultra-affordable drug therapies at global scale.

Papillon unlocks a paradigm shift for pharmaceutical companies developing new inhaled drugs: unit dose costs competitive to multi-dose inhalers at a fraction of the development cost and risk associated with complex devices.

Hovione Technology’s CEO Peter Villax said: “This is a strategic DPI development for Hovione Technology which emphasises our long-term commitment to offer market access to a portfolio of innovative inhalers that maximise simplicity of use, drug delivery performance and cost-effectiveness on a truly global scale. We are delighted to accelerate commercialisation of this innovative blister DPI.”

Hovione Technology has a co-promotional agreement with active pharmaceutical ingredient manufacturer Hovione and together they are able to provide access to a complete portfolio of innovative DPI devices integrated with inhalation API, formulation development and industrial manufacturing to pharmaceutical companies focusing on inhaled drugs.